69 related articles for article (PubMed ID: 38615745)
21. Signal transducer and activator of transcription 3 inhibitors: a patent review.
Page BD; Ball DP; Gunning PT
Expert Opin Ther Pat; 2011 Jan; 21(1):65-83. PubMed ID: 21114420
[TBL] [Abstract][Full Text] [Related]
22. Recent Update on Development of Small-Molecule STAT3 Inhibitors for Cancer Therapy: From Phosphorylation Inhibition to Protein Degradation.
Dong J; Cheng XD; Zhang WD; Qin JJ
J Med Chem; 2021 Jul; 64(13):8884-8915. PubMed ID: 34170703
[TBL] [Abstract][Full Text] [Related]
23. Signal transducer and activator of transcription 3 (STAT3): a promising target for anticancer therapy.
Masciocchi D; Gelain A; Villa S; Meneghetti F; Barlocco D
Future Med Chem; 2011 Apr; 3(5):567-97. PubMed ID: 21526897
[TBL] [Abstract][Full Text] [Related]
24. Strategies and Approaches of Targeting STAT3 for Cancer Treatment.
Furtek SL; Backos DS; Matheson CJ; Reigan P
ACS Chem Biol; 2016 Feb; 11(2):308-18. PubMed ID: 26730496
[TBL] [Abstract][Full Text] [Related]
25. Inhibiting signal transducer and activator of transcription 3: rationality and rationale design of inhibitors.
Mankan AK; Greten FR
Expert Opin Investig Drugs; 2011 Sep; 20(9):1263-75. PubMed ID: 21751940
[TBL] [Abstract][Full Text] [Related]
26. Targeting STAT3 in Cancer Immunotherapy.
Zou S; Tong Q; Liu B; Huang W; Tian Y; Fu X
Mol Cancer; 2020 Sep; 19(1):145. PubMed ID: 32972405
[TBL] [Abstract][Full Text] [Related]
27. Targeting STAT3 in cancer: how successful are we?
Yue P; Turkson J
Expert Opin Investig Drugs; 2009 Jan; 18(1):45-56. PubMed ID: 19053881
[TBL] [Abstract][Full Text] [Related]
28. STAT proteins as novel targets for cancer drug discovery.
Turkson J
Expert Opin Ther Targets; 2004 Oct; 8(5):409-22. PubMed ID: 15469392
[TBL] [Abstract][Full Text] [Related]
29. An update on investigational therapies that target STAT3 for the treatment of cancer.
Santoni M; Miccini F; Cimadamore A; Piva F; Massari F; Cheng L; Lopez-Beltran A; Montironi R; Battelli N
Expert Opin Investig Drugs; 2021 Mar; 30(3):245-251. PubMed ID: 33599169
[TBL] [Abstract][Full Text] [Related]
30. Investigational therapies targeting signal transducer and activator of transcription 3 for the treatment of cancer.
Santoni M; Massari F; Del Re M; Ciccarese C; Piva F; Principato G; Montironi R; Santini D; Danesi R; Tortora G; Cascinu S
Expert Opin Investig Drugs; 2015 Jun; 24(6):809-24. PubMed ID: 25746129
[TBL] [Abstract][Full Text] [Related]
31. Revisiting signal transducer and activator of transcription 3 (STAT3) as an anticancer target and its inhibitor discovery: Where are we and where should we go?
Huang Q; Zhong Y; Dong H; Zheng Q; Shi S; Zhu K; Qu X; Hu W; Zhang X; Wang Y
Eur J Med Chem; 2020 Feb; 187():111922. PubMed ID: 31810784
[TBL] [Abstract][Full Text] [Related]
32. Revisiting STAT3 signalling in cancer: new and unexpected biological functions.
Yu H; Lee H; Herrmann A; Buettner R; Jove R
Nat Rev Cancer; 2014 Nov; 14(11):736-46. PubMed ID: 25342631
[TBL] [Abstract][Full Text] [Related]
33. The JAK/STAT3 axis: A comprehensive drug target for solid malignancies.
Huynh J; Etemadi N; Hollande F; Ernst M; Buchert M
Semin Cancer Biol; 2017 Aug; 45():13-22. PubMed ID: 28647610
[TBL] [Abstract][Full Text] [Related]
34. Signal Transducer and Activator of Transcription Protein 3 (STAT3): An Update on its Direct Inhibitors as Promising Anticancer Agents.
Gelain A; Mori M; Meneghetti F; Villa S
Curr Med Chem; 2019; 26(27):5165-5206. PubMed ID: 30027840
[TBL] [Abstract][Full Text] [Related]
35. Role of STAT3 signaling transduction pathways in cancer stem cell-associated chemoresistance.
Shih PC; Mei KC
Drug Discov Today; 2021 Jun; 26(6):1450-1458. PubMed ID: 33307211
[TBL] [Abstract][Full Text] [Related]
36. Novel activators and small-molecule inhibitors of STAT3 in cancer.
Yang L; Lin S; Xu L; Lin J; Zhao C; Huang X
Cytokine Growth Factor Rev; 2019 Oct; 49():10-22. PubMed ID: 31677966
[TBL] [Abstract][Full Text] [Related]
37. Signal transducer and activator of transcription proteins: regulators of myeloid-derived suppressor cell-mediated immunosuppression in cancer.
Ko HJ; Kim YJ
Arch Pharm Res; 2016 Nov; 39(11):1597-1608. PubMed ID: 27572156
[TBL] [Abstract][Full Text] [Related]
38. Two decades of research in discovery of anticancer drugs targeting STAT3, how close are we?
Beebe JD; Liu JY; Zhang JT
Pharmacol Ther; 2018 Nov; 191():74-91. PubMed ID: 29933035
[TBL] [Abstract][Full Text] [Related]
39. Small molecule inhibitors of STAT3 for cancer therapy.
Zhao M; Jiang B; Gao FH
Curr Med Chem; 2011; 18(26):4012-8. PubMed ID: 21824090
[TBL] [Abstract][Full Text] [Related]
40. Biological Hallmarks and Emerging Strategies to Target STAT3 Signaling in Multiple Myeloma.
Zhou J; Chng WJ
Cells; 2022 Mar; 11(6):. PubMed ID: 35326392
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]